Search Results - "Somavarapu, S"

Refine Results
  1. 1

    Development of Novel Octanoyl Chitosan Nanoparticles for Improved Rifampicin Pulmonary Delivery: Optimization by Factorial Design by Petkar, Kailash C., Chavhan, Sandip, Kunda, N., Saleem, I., Somavarapu, S., Taylor, Kevin M. G., Sawant, Krutika K.

    Published in AAPS PharmSciTech (01-05-2018)
    “…A novel hydrophobic chitosan derivative, octanoyl chitosan (OC) with improved organic solubility was synthesized, characterized, and employed for the…”
    Get full text
    Journal Article
  2. 2

    A new model for a drying droplet by Sazhin, S.S., Rybdylova, O., Pannala, A.S., Somavarapu, S., Zaripov, S.K.

    “…•A new mathematical model for droplet drying.•Analysis of drying of a spray consisting of chitosan dissolved in water.•Validation of the model against…”
    Get full text
    Journal Article
  3. 3

    Mono- N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery by Sayın, B., Somavarapu, S., Li, X.W., Thanou, M., Sesardic, D., Alpar, H.O., Şenel, S.

    Published in International journal of pharmaceutics (03-11-2008)
    “…Mucosal application of a vaccine can effectively induce both systemic and mucosal immune responses. In general, mucosal applications of antigens result in poor…”
    Get full text
    Journal Article
  4. 4

    Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery by Alpar, H. Oya, Somavarapu, S., Atuah, K.N., Bramwell, V.W.

    Published in Advanced drug delivery reviews (10-01-2005)
    “…Biodegradable polymer and particulate carriers have been shown to be of considerable potential for the delivery of peptides, proteins and DNA in animal models…”
    Get full text
    Journal Article
  5. 5

    Intranasal vaccination against plague, tetanus and diphtheria by Alpar, H.O, Eyles, J.E, Williamson, E.D, Somavarapu, S

    Published in Advanced drug delivery reviews (23-09-2001)
    “…Plague is an extremely virulent and potentially lethal infection caused by the bacterium Y. pestis. The current vaccine used to immunise against plague often…”
    Get full text
    Journal Article
  6. 6

    Adjuvant synergy: The effects of nasal coadministration of adjuvants by Moschos, SA, Bramwell, VW, Somavarapu, S, Alpar, HO

    Published in Immunology and cell biology (01-12-2004)
    “…Modern peptide and protein subunit vaccines suffer from poor immunogenicity and require the use of adjuvants. However, none of the currently licensed adjuvants…”
    Get full text
    Journal Article
  7. 7

    Effect of Vitamin E TPGS on immune response to nasally delivered diphtheria toxoid loaded poly(caprolactone) microparticles by Somavarapu, S., Pandit, S., Gradassi, G., Bandera, M., Ravichandran, E., Alpar, Oya H.

    Published in International journal of pharmaceutics (25-07-2005)
    “…The nasal mucosa has many advantages as a potential site for drug and vaccine delivery. The present study has sought to exploit this route of delivery using…”
    Get full text
    Journal Article Conference Proceeding
  8. 8

    Immunisation against plague by transcutaneous and intradermal application of subunit antigens by Eyles, J.E., Elvin, S.J., Westwood, A., LeButt, C.S., Alpar, H.O., Somavarapu, S., Williamson, E.D.

    Published in Vaccine (22-10-2004)
    “…We have investigated immunological responses in BALB/c mice following transcutaneous (TC) delivery of fraction 1 (F1) and V subunits from Yersinia pestis in…”
    Get full text
    Journal Article
  9. 9

    Immobilisation of vaccines onto micro-crystals for enhanced thermal stability by Murdan, S., Somavarapu, S., Ross, Alistair C., Alpar, H.O., Parker, M.C.

    Published in International journal of pharmaceutics (30-05-2005)
    “…The thermal instability of many vaccines leads to the wastage of half of all supplied vaccines. In this note, we report the application of a novel technology:…”
    Get full text
    Journal Article
  10. 10

    Adjuvant Action of Melittin Following Intranasal Immunisation with Tetanus and Diphtheria Toxoids by Bramwell, V.W., Somavarapu, S., Outschoorn, I., Alpar, H.O.

    Published in Journal of drug targeting (2003)
    “…Melittin, a 26-amino acid peptide and the major active component of the venom of the honey bee-Apis mellifera-has recently been shown to have absorption…”
    Get full text
    Journal Article
  11. 11

    Nanoparticle agglomerates of indomethacin: The role of poloxamers and matrix former on their dissolution and aerosolisation efficiency by Malamatari, Maria, Somavarapu, Satyanarayana, Bloxham, Mark, Buckton, Graham

    Published in International journal of pharmaceutics (10-11-2015)
    “…[Display omitted] Nanoparticles (NPs) were prepared and assembled to microsized agglomerates with and without matrix formers (mannitol and l-leucine) by…”
    Get full text
    Journal Article
  12. 12

    Oral Plasmid DNA Delivery Systems for Genetic Immunisation by Somavarapu, S., Bramwell, V.W., Alpar, H.O.

    Published in Journal of drug targeting (2003)
    “…The use and optimisation of plasmid DNA delivery systems for the purposes of eliciting transgene specific immune responses to orally administered DNA encoded…”
    Get full text
    Journal Article
  13. 13

    Mucosal delivery of diphtheria toxoid using polymer-coated-bioadhesive liposomes as vaccine carriers by Martin, C., Somavarapu, S., Alpar, H.O.

    “…The aim of this study was to prepare stable liposomes coated or loaded with bioadhesive polymers and test their efficacy following oral, nasal (IN) or…”
    Get full text
    Journal Article
  14. 14

    Preparation of respirable nanoparticle agglomerates of the low melting and ductile drug ibuprofen: Impact of formulation parameters by Malamatari, Maria, Somavarapu, Satyanarayana, Kachrimanis, Kyriakos, Buckton, Graham, Taylor, Kevin M.G.

    Published in Powder technology (15-02-2017)
    “…Ductile and low melting point drugs exhibit challenging behaviour during both particle size reduction and spray drying as considerable amount of heat is…”
    Get full text
    Journal Article
  15. 15

    Hydrophobically modified chitosan nanoliposomes for intestinal drug delivery by Zariwala, M Gulrez, Bendre, Harshada, Markiv, Anatoliy, Farnaud, Sebastien, Renshaw, Derek, Taylor, Kevin Mg, Somavarapu, Satyanarayana

    Published in International journal of nanomedicine (01-01-2018)
    “…Encapsulation of hydrophilic drugs within liposomes can be challenging. A novel chitosan derivative, O-palmitoyl chitosan (OPC) was synthesized from chitosan…”
    Get full text
    Journal Article
  16. 16

    Novel biodegradable poly(gamma-glutamic acid)-amphotericin B complexes show promise as improved amphotericin B formulations by Dinh, T, Zia, Q, Zubair, S, Stapleton, P, Singh, R, Owais, M, Somavarapu, S

    Published in Nanomedicine (01-07-2017)
    “…Abstract Commercially available amphotericin B (AmB) formulations are limited either by cytotoxicities, lower efficacies, shelf-life related issues or high…”
    Get full text
    Journal Article
  17. 17
  18. 18

    Formulation of a microparticle carrier for oral polyplex-based DNA vaccines by Howard, Kenneth A., Li, Xiong Wei, Somavarapu, Satyanarayana, Singh, Jasvinder, Green, Nicky, Atuah, Kwame N., Ozsoy, Yildiz, Seymour, Leonard W., Alpar, H.Oya

    Published in Biochimica et biophysica acta (24-09-2004)
    “…Oral induction of a disseminated mucosal immune response with polyplex-based DNA vaccines requires the delivery of intact polyplexes (polyelectrolyte complexes…”
    Get full text
    Journal Article
  19. 19

    Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation by Moschos, Sterghios A., Bramwell, Vincent W., Somavarapu, Satyanarayna, Alpar, H. Oya

    Published in Vaccine (14-03-2005)
    “…As the precise functions of adjuvants become clearer, opportunities are presented in their complementary use for the induction of tailored immune responses to…”
    Get full text
    Journal Article
  20. 20

    Modulating the adjuvanticity of alum by co-administration of muramyl di-peptide (MDP) or Quil-A by Moschos, Sterghios A., Bramwell, Vincent W., Somavarapu, Satyanarayna, Alpar, H. Oya

    Published in Vaccine (20-02-2006)
    “…The characterization of the immunological cascades of the innate immune system activated by pathogen associated molecular patterns (PAMP) recognized by pattern…”
    Get full text
    Journal Article